Tianeptine
Viewing r1 — Apr 26, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Tianeptine — ZaZa, gas station heroin — is a synthetic antidepressant of the dibenzothiazepine class. Despite a tricyclic structure, it works very differently from classical tricyclics like imipramine. It activates opioid receptors in the brain, producing quiet mood correction at therapeutic doses and sedation and euphoria at high ones.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
morphine, oxycodone, hydrocodone +4 moremorphine, oxycodone, hydrocodone, heroin, tramadol, codeine, fentanyl show less
Synthesized around 1970, tianeptine entered clinical use in France as Stablon by 1983.[1] For three decades it was thought to work through serotonin until a 2014 study revealed it as a μ-opioid agonist,[2] rewriting the science. It is now prescribed in about 66 countries but remains unregulated in the United States, where it circulates as a gas station supplement.[1]
Subjective effects include mood elevation, anxiety relief, sedation, and euphoria. At prescribed doses the experience is quiet — a background reduction in distress without a recognizable high; at high doses, opioid warmth and heavy sedation take over.[2] Nausea, slowed breathing, and strong pressure to redose are the characteristic unwanted effects.[3]
At high doses tianeptine produces severe physical dependence and dangerous respiratory depression.[3] The short half-life drives withdrawal between doses, pushing users from milligrams to grams within weeks; combining with alcohol or other sedatives amplifies overdose risk.[4] Decades of prescription data exist, but whether opioid receptor activation fully explains the antidepressant effect remains unresolved.[5]
History[edit]
Discovery
Tianeptine was synthesized around 1970 and entered clinical use in France as Stablon by 1983.[1] It was initially described as a "serotonin reuptake enhancer" — an unusual claim that ran counter to mainstream antidepressant theory.[6] That framing made it a research curiosity for decades rather than an accepted mechanism.
Scientific Significance
Through the 1990s, research showed tianeptine prevents and reverses stress-induced shrinkage of hippocampal neurons — effects that fluoxetine failed to replicate.[7][8] In 2014, researchers at Columbia University identified it as a full mu-opioid receptor agonist,[2] revising three decades of mechanistic assumptions. The finding immediately raised questions about its abuse potential.
Emergence as a Drug of Abuse
In the United States, tianeptine entered the recreational market through supplement loopholes, sold at gas stations as "ZaZa," "Tianaa," and "Tianna".[3] Alabama classified it as Schedule I in 2021, followed by Florida in 2023.[9] As of 2026, it remains prescribed in approximately 66 countries and federally unscheduled in the United States.[1]
The name tianeptine comes from its chemical structure — the thiazepine ring system with an amino side chain. The nicknames "ZaZa" and "gas station heroin" capture both its commercial branding and its opioid character at high doses. A prescription antidepressant sold alongside energy drinks: the image drove both media attention and legislative action.
Chemistry[edit]
Structural Class
Tianeptine is a dibenzothiazepine — a modified tricyclic compound with a sulfonyl-bridged ring system and a heptanoic acid side chain.[5]
Despite the tricyclic scaffold, it lacks the anticholinergic and antihistaminic properties of classical tricyclics like imipramine and amitriptyline. Its molecular formula is C₂₁H₂₅ClN₂O₄S (molecular weight 437.0 g/mol).
Pharmacology[edit]
Mechanism of Action
Tianeptine is a full agonist at mu-opioid receptors — the same receptors activated by morphine.[2] Its antidepressant effect depends entirely on these receptors; removing them from animal models abolishes the effect completely.[10] Contrary to what was believed for decades, serotonin plays no role.[5]
Pharmacokinetics
Tianeptine is nearly completely absorbed orally and reaches peak blood levels within an hour.[11][12] Its half-life is approximately 2.5 hours, requiring three doses per day and driving the interdose withdrawal that accelerates addiction. It is broken down through a fatty acid pathway rather than the liver enzymes that process most drugs,[6] giving it a low risk of drug interactions.
Neuroscience[edit]
Where It Acts
Tianeptine's antidepressant effect is localized to a specific set of inhibitory neurons in the hippocampus.[13] These neurons gate signals from the hippocampus to mood-regulating circuits. Dampening them through opioid receptor activation produces quiet mood correction — without the broader opioid effects that generate heavy sedation and euphoria.[10]
Why It Matters
At high doses, tianeptine recruits the brain's mesolimbic pathway, producing euphoria and the compulsive reinforcement characteristic of opioid agonists.[3] It also protects hippocampal neurons from stress-related shrinkage[7][8] and reduces brain inflammation.[14][15] These converging effects place it at the intersection of three major theories of antidepressant action.
Whether opioid receptor activation alone explains tianeptine's antidepressant effect — or whether glutamate signaling operates as a parallel mechanism — remains unresolved.[5] The basis for the sharp transition between a well-tolerated antidepressant at therapeutic doses and a compulsively used opioid at high doses also lacks a clear explanation. The two mirror-image forms of the molecule may differ in opioid receptor activity, but no in vivo data exist.[16]
Subjective Effects[edit]
At therapeutic doses, tianeptine produces a quiet, functional mood lift — distress recedes and anxiety clears without a recognizable drug feeling. At high doses the character changes completely: opioid warmth, heavy sedation, and euphoria replace the background calm.[2] Context shapes which experience emerges.
Among opioids, supratherapeutic tianeptine most closely resembles tramadol — a moderate, short-acting warmth with strong anxiolysis. The near-complete oral absorption and ultra-short half-life create a compressed cycle: effects peak quickly and fade within hours, with withdrawal beginning shortly after.[11]
Effect Grid
At common doses (25–50 mg oral, single dose), anxiolysis becomes more pronounced and mood elevation is clearly perceptible. Motivation enhancement and a sense of emotional warmth emerge. Cognitive effects remain neutral to mildly positive — tianeptine was superior to escitalopram on cognitive measures in clinical trials at this therapeutic range.
Physically, mild stimulation may be noted. Constipation and nausea are possible but uncommon. No cardiovascular changes. Duration remains approximately 2–4 hours, with the MC5 metabolite contributing to a subtle tail of residual effects.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Tactile euphoria · Muscle relaxation · Nausea · Constipation · Sedation · Insomnia · Restlessness · Bodily heaviness · Physical fatigue · Dizziness · Excessive sweating · Muscle tension · Stimulation · Spontaneous body sensations · Headache · Yawning · Watery eyes · Trembling · Diarrhea · Brain zaps · Dry mouth · Sexual arousal suppression · Appetite suppression · Vomiting · Motor control impairment · Tingling / electric sensations · Pain enhancement
Constipation · Sedation · Insomnia · Restlessness · Bodily heaviness · Physical fatigue · Dizziness · Excessive sweating · Muscle tension · Stimulation · Spontaneous body sensations · Headache · Yawning · Watery eyes · Trembling · Diarrhea · Brain zaps · Dry mouth · Sexual arousal suppression · Appetite suppression · Vomiting · Tingling / electric sensations · Pain enhancement
Motivation suppression · Motivation enhancement · Cognitive impairment · Focus enhancement · Focus suppression · Thought deceleration · Confusion · Information processing suppression · Thought acceleration · Thought disorganization · Memory suppression
Focus suppression · Thought deceleration · Confusion · Information processing suppression · Thought acceleration · Thought disorganization · Memory suppression
Anhedonia · Dysphoria · Emotional suppression
Depersonalization · Disinhibition
Timeline
First perceptible effects emerge as a subtle shift in background mood and a mild reduction in anxiety. Physically unremarkable.
Anxiolysis and mood elevation build toward peak intensity. At supratherapeutic doses, warmth and the first hints of opioid-like euphoria become apparent.
Maximum subjective intensity coinciding with Tmax (~56 minutes post-ingestion). Anxiolysis, mood elevation, and at higher doses euphoria and muscle relaxation are at their strongest. Cognitive function preserved at therapeutic doses.
Effects decline in parallel with the short elimination half-life (~2. 5 hours). At supratherapeutic doses, interdosing withdrawal cues may emerge during this phase, driving compulsive redosing.
Residual anxiolysis and subtle mood effects persist, likely mediated by the MC5 metabolite (t1/2 ~7. 2 hours). Functional impairment is minimal at therapeutic doses.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Severe
- Tolerance buildup
- rapid
- Tolerance reset
- —
- Physical
- High
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- High
- Cross-tol.
- morphine · oxycodone · hydrocodone
Toxicity
Acute Toxicity
At the standard therapeutic dose of 37.5 mg/day, tianeptine has a favorable safety profile with no organ toxicity. At high doses — 1–10 g/day documented in abuse cases — it produces opioid overdose: deep sedation, slowed breathing, and loss of consciousness.[3] These effects partially or fully reverse with naloxone.[3]
One confirmed fatality involved a 26-year-old male with co-ingested alcohol.[4] A 2025 systematic review notes increasing fatal outcomes associated with tianeptine misuse.[17]
Cardiovascular Safety
At therapeutic doses, tianeptine does not affect heart rate, blood pressure, or cardiac rhythm.[18] Clinical data from over 3,300 patients confirm cardiovascular safety over up to one year.[19][20] This contrasts sharply with classical tricyclic antidepressants, which carry significant cardiac risk.
Liver Toxicity
Liver damage is rare. No dose adjustment is required for liver impairment or alcoholism.[6]
Neonatal Exposure
Tianeptine crosses the placenta. A documented case of severe neonatal opioid withdrawal required treatment with oral morphine after phenobarbital failed.[21] Tianeptine is not detected by routine urine drug screens, creating diagnostic challenges when infants present with unexplained withdrawal symptoms.
Diagnostic Challenge
Tianeptine does not appear on standard opioid urine drug screens.[21] A patient presenting with opioid overdose symptoms may test negative on standard screening. Specialized laboratory testing is required for confirmation.
Psychological Risks
Case reports describe compulsive use, preoccupation with obtaining supply, and continued use despite deteriorating health[22] — a pattern consistent with opioid use disorder. The anxiolytic effect is a primary driver of early dose escalation.[23] No psychosis or psychiatric destabilization at therapeutic doses has been reported.[6]
Tolerance and Dependence
At the standard therapeutic dose, tianeptine has low abuse potential.[6] Animal models show no tolerance or withdrawal at clinically relevant doses.[24] At abuse doses, the dependence profile is severe and opioid-like.[3]
Escalation from therapeutic doses to grams per day can occur within weeks to months.[3] Withdrawal symptoms — anxiety, agitation, nausea, vomiting, sweating, muscle pain, and cravings — begin quickly after the last dose, consistent with the 2.5-hour half-life.[25][22] The short half-life drives a cycle of interdose withdrawal that accelerates dose escalation.
Buprenorphine-naloxone is first-line treatment for tianeptine withdrawal and maintenance.[22][23][26] Microdose induction has been described.[26] Clonidine may serve as an adjunct.[25] Methadone has been used in complex cases.[27] Relapse rates are high; long-term follow-up and residential treatment are recommended for severe cases.
Recovery resources, crisis lines, and support pathways → View all
Drug Interactions
Alcohol reduces tianeptine absorption by about 30%[11] but amplifies overdose risk — the only confirmed fatality involved the combination.[4] Other opioids and sedatives (including benzodiazepines like etizolam) add to sedation and respiratory depression.[28][27]
No published interaction data exist for monoamine oxidase inhibitors; standard precautions and a 14-day washout period apply.[6] Serotonin syndrome risk is low — tianeptine is not a significant serotonergic agent at standard doses. Beta-oxidation metabolism confers lower CYP450 interaction risk than most antidepressants.[6]
Contraindications
Pregnancy is an absolute contraindication: tianeptine crosses the placenta and causes severe neonatal withdrawal requiring opioid treatment.[21] Severe kidney impairment requires dose reduction due to prolonged elimination.[12]
Relative contraindications include concurrent opioid use (additive respiratory depression, compounded by tianeptine's invisibility on standard drug screens), alcohol use disorder (amplified overdose risk[4]), and pre-existing breathing disorders (opioid-mediated respiratory suppression at high doses).
Harm Reduction[edit]
Forms & Identification
Tianeptine comes in two forms: pharmaceutical tablets (12.5 mg sodium salt, branded Stablon or Coaxil) and unregulated supplement products (capsules or powders sold as "Tianaa," "ZaZa," and similar names). Pharmaceutical forms are reliably dosed. Supplement forms are not — labeled amounts cannot be trusted without analytical testing.
Guidelines
- Test unregulated products with an analytical service before use — labeled content does not guarantee actual content or dose
- Do not exceed 37.5 mg total per day (12.5 mg three times daily) — the established therapeutic ceiling
- Time doses at least 4–6 hours apart to avoid stacking
- Track daily consumption carefully — dose escalation often begins subtly and accelerates quickly
- Do not use tianeptine to manage acute emotional distress — the short half-life makes it poorly suited to crisis self-medication and creates a redosing cycle
- Keep a written log of doses and amounts — if the log shows increasing use over days or weeks, this is an early warning sign
Set & Setting
Prescribed use within a clinical relationship rarely leads to dependence. Unsupervised use of unregulated products, especially to manage anxiety, carries high escalation risk. The short duration of effects creates pressure to redose — a feeling that can mimic insufficient dosing but is the compound's pharmacokinetics at work.
Aftercare & integration. After stopping high-dose tianeptine use, physical recovery takes priority. Opioid-type withdrawal typically peaks within 24–72 hours given the short half-life. Adequate hydration, rest, and nutritional support help manage acute symptoms.
Sleep disruption, anxiety, and low mood commonly persist for days to weeks. These are expected features of opioid withdrawal recovery, not signs of treatment failure. Professional support — particularly buprenorphine-based medication — significantly improves outcomes.
Recovery & Support
Tianeptine use disorder follows opioid use disorder patterns and responds to the same evidence-based treatments. Buprenorphine-naloxone (Suboxone) is first-line medication-assisted treatment.[22] Treatment providers should be told that tianeptine is an opioid agonist — many clinicians are unfamiliar with it.
Relapse rates are high. Long-term medication-assisted treatment, ongoing therapeutic support, and — for severe cases — residential treatment improve outcomes. Peer support and opioid recovery groups provide additional structure during maintenance.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Slow or stopped breathing, blue lips or fingernails, unresponsiveness to voice or touch, pinpoint pupils, or loss of consciousness after tianeptine use indicate opioid overdose. Deep sedation that does not respond to loud voice or physical stimulation requires immediate intervention.
Immediate steps:
- 1. Call emergency services immediately
- 2. Administer naloxone if available — tianeptine overdose responds to naloxone[3]
- 3. A second naloxone dose may be required given its short duration of action
- 4. Place the person in the recovery position (on their side) to prevent aspiration
- 5. Stay with the person until help arrives and monitor breathing continuously
- 6. Do not induce vomiting
What to tell the dispatcher: State that the person has taken tianeptine (an opioid agonist), the approximate amount if known, the time of last dose, and current symptoms. Note that tianeptine will not appear on standard drug screens. Good Samaritan laws in many jurisdictions protect people who call for help during an overdose.
Reversal agent: Naloxone (Narcan) reverses tianeptine overdose. Because tianeptine's effects may outlast naloxone's duration of action, the person can re-sedate after naloxone wears off — ongoing monitoring is essential.
Legal Status[edit]
Tianeptine's legal status varies sharply by jurisdiction — a prescription antidepressant in over 60 countries, but controlled or unscheduled depending on where one is, with the US landscape evolving rapidly.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States (federal) | Not scheduled under the Controlled Substances Act | FDA consumer warning January 2024: tianeptine unlawful in food or dietary supplements. STAND Against Emerging Opioids Act proposed Schedule III classification[9] |
| Alabama | Schedule I (state) | Effective November 14, 2021[9] |
| Florida | Schedule I (state) | Emergency adoption effective September 20, 2023[9] |
| Kentucky, Michigan, Minnesota, Mississippi, Ohio | Controlled substance (state-level) | Various restrictions in place[9] |
| France | Approved prescription drug | Trade name Stablon; Laboratoires Servier; approved ~1983–1989[1] |
| European Union (~15 states) | Approved prescription drug | Available in France, Portugal, Bulgaria, Romania, Slovakia, Poland, Malta, Hungary, Lithuania, Slovenia, Czech Republic, Austria, Latvia, Estonia, Luxembourg. Trade names: Stablon, Coaxil[1] |
| United Kingdom | Not approved | Not available[1] |
| Canada | Not approved | Not available |
| Australia | Not approved | Not listed on ARTG; TGA has considered scheduling |
| Global | Varies | Marketed in 66+ countries across Europe (excluding UK, Italy), Asia (Singapore, Japan), Latin America[1] |
As of early 2026, tianeptine remains federally unscheduled in the United States, but the FDA's January 2024 warning and the proposed STAND Act represent movement toward federal control. Multiple states have enacted Schedule I or equivalent restrictions, creating a patchwork of state-level regulation.[9]
Legal status changes frequently and varies by state and country. This information reflects the situation as of early 2026 and is not legal advice.
references
- [1]
- [2]
- [3]
- [4] ^abcdProenca P, Teixeira H, Pinheiro J, Monsanto PV, Vieira DN (2007) Fatal intoxication with tianeptine (Stablon) — Forensic Science International PMID:17630235
- [5] ^abcdNishio Y, Lindsley CW, Bender AM (2024) Classics in Chemical Neuroscience: Tianeptine — ACS Chemical Neuroscience doi:10.1021/acschemneuro.4c00519
- [6]